Bioventus Pocfratio vs Price To Sales Ratio Analysis

BVS Stock

USD 11.71 0.20 1.74%

Bioventus financial indicator trend analysis is way more than just evaluating Bioventus prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Bioventus is a good investment. Please check the relationship between Bioventus Pocfratio and its Price To Sales Ratio accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bioventus. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Bioventus Stock please use our How to Invest in Bioventus guide.

Pocfratio vs Price To Sales Ratio

Pocfratio vs Price To Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Bioventus Pocfratio account and Price To Sales Ratio. At this time, the significance of the direction appears to have strong relationship.

The correlation between Bioventus' Pocfratio and Price To Sales Ratio is 0.61. Overlapping area represents the amount of variation of Pocfratio that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Bioventus, assuming nothing else is changed. The correlation between historical values of Bioventus' Pocfratio and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Pocfratio of Bioventus are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Pocfratio i.e., Bioventus' Pocfratio and Price To Sales Ratio go up and down completely randomly.

Correlation Coefficient

0.61

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Pocfratio

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Bioventus stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Bioventus sales, a figure that is much harder to manipulate than other Bioventus multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Most indicators from Bioventus' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Bioventus current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bioventus. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.

For more information on how to buy Bioventus Stock please use our How to Invest in Bioventus guide.Enterprise Value is likely to gain to about 1.2 B in 2024, whereas Discontinued Operations is likely to drop (2.2 M) in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	1.1M	25.8M	40.7M	42.7M
Depreciation And Amortization	38.7M	61.4M	57.4M	40.7M

Interest Expense Depreciation And Amortization

Bioventus fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt
Common Stock Shares Outstanding		0.76	0.88	0.77	0.8	0.5	0.87	-0.15	0.82	-0.73	0.78	0.24	0.7	-0.29	0.24	0.83	-0.34	-0.67	0.77	0.87	0.94	0.92	0.79	0.97	0.82	0.66
Total Assets	0.76		0.93	0.93	0.94	0.86	0.86	0.17	0.9	-0.22	0.9	0.13	0.99	-0.48	0.13	0.87	0.11	-0.66	0.98	0.86	0.77	0.86	0.97	0.6	0.82	0.65
Short Long Term Debt Total	0.88	0.93		0.9	0.93	0.67	0.94	0.0	0.97	-0.49	0.94	0.17	0.88	-0.43	0.17	0.93	-0.11	-0.65	0.94	0.98	0.86	0.92	0.94	0.77	0.89	0.7
Other Current Liab	0.77	0.93	0.9		0.98	0.66	0.89	0.11	0.83	-0.35	0.89	0.3	0.89	-0.56	0.3	0.89	-0.1	-0.55	0.95	0.86	0.71	0.81	0.96	0.63	0.87	0.66
Total Current Liabilities	0.8	0.94	0.93	0.98		0.65	0.89	0.04	0.87	-0.42	0.94	0.26	0.9	-0.61	0.26	0.91	-0.15	-0.55	0.97	0.89	0.72	0.82	0.98	0.65	0.88	0.74
Total Stockholder Equity	0.5	0.86	0.67	0.66	0.65		0.62	0.44	0.69	0.19	0.58	-0.05	0.89	-0.13	-0.05	0.6	0.53	-0.67	0.74	0.56	0.66	0.69	0.72	0.37	0.54	0.45
Property Plant And Equipment Net	0.87	0.86	0.94	0.89	0.89	0.62		0.09	0.88	-0.47	0.83	0.26	0.8	-0.32	0.26	0.89	-0.09	-0.67	0.85	0.94	0.86	0.84	0.87	0.81	0.89	0.71
Current Deferred Revenue	-0.15	0.17	0.0	0.11	0.04	0.44	0.09		-0.13	0.44	-0.2	0.51	0.13	0.51	0.51	0.21	0.85	0.23	0.02	-0.13	0.06	-0.06	0.03	-0.2	0.27	-0.08
Net Debt	0.82	0.9	0.97	0.83	0.87	0.69	0.88	-0.13		-0.4	0.94	-0.08	0.89	-0.48	-0.08	0.81	-0.11	-0.77	0.91	0.97	0.82	0.91	0.91	0.72	0.75	0.72
Retained Earnings	-0.73	-0.22	-0.49	-0.35	-0.42	0.19	-0.47	0.44	-0.4		-0.46	-0.38	-0.11	0.19	-0.38	-0.54	0.73	0.14	-0.32	-0.55	-0.56	-0.52	-0.35	-0.78	-0.56	-0.42
Accounts Payable	0.78	0.9	0.94	0.89	0.94	0.58	0.83	-0.2	0.94	-0.46		0.04	0.88	-0.7	0.04	0.84	-0.26	-0.6	0.96	0.93	0.69	0.83	0.96	0.63	0.78	0.69
Cash	0.24	0.13	0.17	0.3	0.26	-0.05	0.26	0.51	-0.08	-0.38	0.04		0.0	0.16	1.0	0.51	0.02	0.45	0.14	0.07	0.19	0.06	0.18	0.22	0.59	-0.04
Non Current Assets Total	0.7	0.99	0.88	0.89	0.9	0.89	0.8	0.13	0.89	-0.11	0.88	0.0		-0.51	0.0	0.79	0.15	-0.71	0.96	0.81	0.72	0.83	0.95	0.53	0.72	0.63
Non Currrent Assets Other	-0.29	-0.48	-0.43	-0.56	-0.61	-0.13	-0.32	0.51	-0.48	0.19	-0.7	0.16	-0.51		0.16	-0.33	0.52	0.26	-0.62	-0.45	-0.05	-0.29	-0.62	-0.12	-0.26	-0.35
Cash And Short Term Investments	0.24	0.13	0.17	0.3	0.26	-0.05	0.26	0.51	-0.08	-0.38	0.04	1.0	0.0	0.16		0.51	0.02	0.45	0.14	0.07	0.19	0.06	0.18	0.22	0.59	-0.04
Net Receivables	0.83	0.87	0.93	0.89	0.91	0.6	0.89	0.21	0.81	-0.54	0.84	0.51	0.79	-0.33	0.51		-0.04	-0.38	0.88	0.86	0.81	0.81	0.9	0.71	0.99	0.61
Good Will	-0.34	0.11	-0.11	-0.1	-0.15	0.53	-0.09	0.85	-0.11	0.73	-0.26	0.02	0.15	0.52	0.02	-0.04		0.06	-0.06	-0.23	-0.05	-0.13	-0.09	-0.38	-0.04	-0.17
Common Stock Total Equity	-0.67	-0.66	-0.65	-0.55	-0.55	-0.67	-0.67	0.23	-0.77	0.14	-0.6	0.45	-0.71	0.26	0.45	-0.38	0.06		-0.6	-0.7	-0.72	-0.77	-0.59	-0.65	-0.33	-0.61
Non Current Liabilities Total	0.77	0.98	0.94	0.95	0.97	0.74	0.85	0.02	0.91	-0.32	0.96	0.14	0.96	-0.62	0.14	0.88	-0.06	-0.6		0.88	0.73	0.84	1.0	0.6	0.83	0.63
Inventory	0.87	0.86	0.98	0.86	0.89	0.56	0.94	-0.13	0.97	-0.55	0.93	0.07	0.81	-0.45	0.07	0.86	-0.23	-0.7	0.88		0.84	0.9	0.89	0.8	0.83	0.77
Other Current Assets	0.94	0.77	0.86	0.71	0.72	0.66	0.86	0.06	0.82	-0.56	0.69	0.19	0.72	-0.05	0.19	0.81	-0.05	-0.72	0.73	0.84		0.95	0.73	0.92	0.8	0.6
Other Stockholder Equity	0.92	0.86	0.92	0.81	0.82	0.69	0.84	-0.06	0.91	-0.52	0.83	0.06	0.83	-0.29	0.06	0.81	-0.13	-0.77	0.84	0.9	0.95		0.84	0.86	0.78	0.65
Total Liab	0.79	0.97	0.94	0.96	0.98	0.72	0.87	0.03	0.91	-0.35	0.96	0.18	0.95	-0.62	0.18	0.9	-0.09	-0.59	1.0	0.89	0.73	0.84		0.62	0.85	0.67
Property Plant And Equipment Gross	0.97	0.6	0.77	0.63	0.65	0.37	0.81	-0.2	0.72	-0.78	0.63	0.22	0.53	-0.12	0.22	0.71	-0.38	-0.65	0.6	0.8	0.92	0.86	0.62		0.72	0.62
Total Current Assets	0.82	0.82	0.89	0.87	0.88	0.54	0.89	0.27	0.75	-0.56	0.78	0.59	0.72	-0.26	0.59	0.99	-0.04	-0.33	0.83	0.83	0.8	0.78	0.85	0.72		0.57
Short Term Debt	0.66	0.65	0.7	0.66	0.74	0.45	0.71	-0.08	0.72	-0.42	0.69	-0.04	0.63	-0.35	-0.04	0.61	-0.17	-0.61	0.63	0.77	0.6	0.65	0.67	0.62	0.57

Click cells to compare fundamentals

Bioventus Account Relationship Matchups

Bioventus fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	56.8M	56.8M	59.5M	61.4M	62.6M	63.5M
Total Assets	472.4M	494.5M	1.2B	1.4B	810.9M	788.8M
Short Long Term Debt Total	198.0M	188.4M	357.7M	418.1M	394.8M	290.3M
Other Current Liab	15.6M	98.8M	134.3M	231.7M	115.0M	86.3M
Total Current Liabilities	89.0M	122.6M	180.9M	304.0M	175.5M	148.1M
Total Stockholder Equity	143.0M	142.2M	458.9M	316.6M	173.6M	240.5M
Property Plant And Equipment Net	19.8M	21.8M	40.2M	45.0M	50.0M	27.7M
Current Deferred Revenue	57.0M	99.2M	142.3M	4.7M	5.5M	5.2M
Net Debt	133.4M	101.5M	313.7M	386.3M	357.9M	245.3M
Retained Earnings	(141.7M)	(144.5M)	(6.6M)	(165.3M)	(321.5M)	(305.5M)
Accounts Payable	6.4M	4.4M	16.9M	36.7M	23.0M	15.1M
Cash	64.5M	86.8M	43.9M	31.8M	37.0M	45.0M
Non Current Assets Total	289.4M	282.7M	962.8M	1.1B	542.9M	576.9M
Non Currrent Assets Other	3.3M	19.4M	50M	(154.0M)	3.1M	3.3M
Cash And Short Term Investments	64.5M	86.8M	43.9M	31.8M	37.0M	45.0M
Net Receivables	85.1M	88.3M	125.0M	136.6M	123.0M	100.7M
Liabilities And Stockholders Equity	472.4M	494.5M	1.2B	1.4B	810.9M	788.8M
Non Current Liabilities Total	237.8M	227.7M	511.2M	728.3M	414.3M	379.4M
Inventory	27.3M	29.1M	61.7M	85.4M	91.3M	52.8M
Other Current Assets	6.1M	7.6M	32.4M	21.1M	33.3M	35.0M
Other Stockholder Equity	(168M)	1.9M	465.3M	490.6M	494.3M	519.0M
Total Liab	326.8M	350.3M	692.1M	1.0B	589.8M	527.5M
Property Plant And Equipment Gross	19.8M	21.8M	40.2M	45.0M	90.5M	95.0M
Total Current Assets	183.0M	211.8M	263.1M	272.6M	268.0M	212.0M
Accumulated Other Comprehensive Income	(465K)	1.6M	179K	(110K)	794K	833.7K
Short Term Debt	10M	17.0M	21.5M	33.1M	32.7M	22.7M
Intangible Assets	216.5M	191.7M	695.2M	1.0B	482.4M	475.1M
Common Stock	285.1M	285.2M	75K	78K	79K	75.1K
Long Term Debt	188.0M	173.4M	339.6M	385.0M	367.0M	301.1M
Net Invested Capital	340.9M	330.6M	816.6M	734.6M	568.4M	574.1M
Long Term Investments	3.3M	19.4M	29.3M	2.6M	3.0M	2.9M
Short Long Term Debt	10M	15M	18.0M	33.1M	27.8M	20.0M
Capital Stock	285.1M	285.2M	75K	78K	79K	75.1K
Non Current Liabilities Other	20.7M	21.7M	38.1M	110.0M	46.1M	44.4M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Bioventus Stock Analysis

When running Bioventus' price analysis, check to measure Bioventus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioventus is operating at the current time. Most of Bioventus' value examination focuses on studying past and present price action to predict the probability of Bioventus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioventus' price. Additionally, you may evaluate how the addition of Bioventus to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC